Review



human per2 hdr plasmid  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology human per2 hdr plasmid
    (A) In silico analysis of <t>PER2</t> mRNA expression in LIHC samples (purple boxplot) from TCGA cohort (obtained from RNAseq) compared with normal liver tissues (grey boxplot); (B) In silico analysis of PER2 mRNA expression in different stages of LIHC; (C) and (D) In silico analysis of PER2 mRNA expression in HCC cell lines from CCLE based on a dataset posted in 2022; (C) A comparison of PER2 mRNA expression between HCC and hepatoblastoma cell lines; and (D) a comparison of PER2 mRNA expression in HCC cell lines derived from human primary HCC, HCC cell lines with no clear origin, and HCC cell lines derived from human HCC metastasis; (E) Kaplan-Meier curve to assess the overall survival rate of patients with HCC depending on the PER2 gene expression; (F) SOR effect on cell line proliferation. Cell proliferation evaluated by DNA assay in PLC/PRF/5 cells: parental (black bars) and SorR (gray bars). The data presented are mean ± SEM of three independent experiments. * P < 0.05, *** P < 0.001 between groups; (G) PER2 mRNA expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, PLC/PRF/5 SorR, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO relative to HPRT housekeeping gene. * P < 0.05; ** P < 0.01; *** P < 0.001; (H) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO with related densitometry. **** P < 0.0001. PER2: Period 2; LIHC: Liver Hepatocellular Carcinoma; CCLE: Cancer Cell Line Encyclopaedia; TCGA: The Cancer Genome Atlas; HCC: hepatocellular carcinoma; SOR: sorafenib; SEM: standard error of the mean; EveR: everolimus-resistant; SorR: sorafenib-resistant; KD: knockdown; KO: knockout; HPRT: Hypoxanthine Phosphoribosyltransferase 1.
    Human Per2 Hdr Plasmid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+per2+hdr+plasmid/pmc12162184-64-17-30?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    human per2 hdr plasmid - by Bioz Stars, 2026-07
    93/100 stars

    Images

    1) Product Images from "PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma"

    Article Title: PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

    Journal: Cancer Drug Resistance

    doi: 10.20517/cdr.2024.193

    (A) In silico analysis of PER2 mRNA expression in LIHC samples (purple boxplot) from TCGA cohort (obtained from RNAseq) compared with normal liver tissues (grey boxplot); (B) In silico analysis of PER2 mRNA expression in different stages of LIHC; (C) and (D) In silico analysis of PER2 mRNA expression in HCC cell lines from CCLE based on a dataset posted in 2022; (C) A comparison of PER2 mRNA expression between HCC and hepatoblastoma cell lines; and (D) a comparison of PER2 mRNA expression in HCC cell lines derived from human primary HCC, HCC cell lines with no clear origin, and HCC cell lines derived from human HCC metastasis; (E) Kaplan-Meier curve to assess the overall survival rate of patients with HCC depending on the PER2 gene expression; (F) SOR effect on cell line proliferation. Cell proliferation evaluated by DNA assay in PLC/PRF/5 cells: parental (black bars) and SorR (gray bars). The data presented are mean ± SEM of three independent experiments. * P < 0.05, *** P < 0.001 between groups; (G) PER2 mRNA expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, PLC/PRF/5 SorR, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO relative to HPRT housekeeping gene. * P < 0.05; ** P < 0.01; *** P < 0.001; (H) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO with related densitometry. **** P < 0.0001. PER2: Period 2; LIHC: Liver Hepatocellular Carcinoma; CCLE: Cancer Cell Line Encyclopaedia; TCGA: The Cancer Genome Atlas; HCC: hepatocellular carcinoma; SOR: sorafenib; SEM: standard error of the mean; EveR: everolimus-resistant; SorR: sorafenib-resistant; KD: knockdown; KO: knockout; HPRT: Hypoxanthine Phosphoribosyltransferase 1.
    Figure Legend Snippet: (A) In silico analysis of PER2 mRNA expression in LIHC samples (purple boxplot) from TCGA cohort (obtained from RNAseq) compared with normal liver tissues (grey boxplot); (B) In silico analysis of PER2 mRNA expression in different stages of LIHC; (C) and (D) In silico analysis of PER2 mRNA expression in HCC cell lines from CCLE based on a dataset posted in 2022; (C) A comparison of PER2 mRNA expression between HCC and hepatoblastoma cell lines; and (D) a comparison of PER2 mRNA expression in HCC cell lines derived from human primary HCC, HCC cell lines with no clear origin, and HCC cell lines derived from human HCC metastasis; (E) Kaplan-Meier curve to assess the overall survival rate of patients with HCC depending on the PER2 gene expression; (F) SOR effect on cell line proliferation. Cell proliferation evaluated by DNA assay in PLC/PRF/5 cells: parental (black bars) and SorR (gray bars). The data presented are mean ± SEM of three independent experiments. * P < 0.05, *** P < 0.001 between groups; (G) PER2 mRNA expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, PLC/PRF/5 SorR, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO relative to HPRT housekeeping gene. * P < 0.05; ** P < 0.01; *** P < 0.001; (H) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO with related densitometry. **** P < 0.0001. PER2: Period 2; LIHC: Liver Hepatocellular Carcinoma; CCLE: Cancer Cell Line Encyclopaedia; TCGA: The Cancer Genome Atlas; HCC: hepatocellular carcinoma; SOR: sorafenib; SEM: standard error of the mean; EveR: everolimus-resistant; SorR: sorafenib-resistant; KD: knockdown; KO: knockout; HPRT: Hypoxanthine Phosphoribosyltransferase 1.

    Techniques Used: In Silico, Expressing, Comparison, Derivative Assay, Gene Expression, Knockdown, Knock-Out

    Evaluation of E-cadherin, vimentin and ZEB1 protein expression by immunofluorescent imaging in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. ZEB1: Zinc finger E-box binding homeobox 1; PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant.
    Figure Legend Snippet: Evaluation of E-cadherin, vimentin and ZEB1 protein expression by immunofluorescent imaging in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. ZEB1: Zinc finger E-box binding homeobox 1; PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant.

    Techniques Used: Expressing, Imaging, Control, Binding Assay, Knockdown, Knock-Out

    Cell proliferation evaluated by DNA assay in PLC/PRF/5 PER2 KD (A) and PLC/PRF/5 PER2 KO (B) with and without treatment with EVE (10 -9 M) and (SOR 5 × 10 -6 M). Cell migration evaluation by analysis of wound coverage in PLC/PRF/5 PER2 KD (C) and PLC/PRF/5 PER2 KO (D) and by scratch assay (E) with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M) compared to parental PLC/PRF/5. The data presented in the graphs are mean ± SEM of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KD: knockdown; KO: knockout; EVE: everolimus; SOR: sorafenib; SEM: standard error of the mean.
    Figure Legend Snippet: Cell proliferation evaluated by DNA assay in PLC/PRF/5 PER2 KD (A) and PLC/PRF/5 PER2 KO (B) with and without treatment with EVE (10 -9 M) and (SOR 5 × 10 -6 M). Cell migration evaluation by analysis of wound coverage in PLC/PRF/5 PER2 KD (C) and PLC/PRF/5 PER2 KO (D) and by scratch assay (E) with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M) compared to parental PLC/PRF/5. The data presented in the graphs are mean ± SEM of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KD: knockdown; KO: knockout; EVE: everolimus; SOR: sorafenib; SEM: standard error of the mean.

    Techniques Used: Migration, Wound Healing Assay, Control, Knockdown, Knock-Out

    Images and statistical assessment of colony number (A, C, E, G and I) and size (B, D, F, H, and L) evaluated by colony formation assay in parental PLC/PRF/5, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and SorR with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M). The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; EVE: everolimus; SOR: sorafenib; SEM:standard error of the mean.
    Figure Legend Snippet: Images and statistical assessment of colony number (A, C, E, G and I) and size (B, D, F, H, and L) evaluated by colony formation assay in parental PLC/PRF/5, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and SorR with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M). The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; EVE: everolimus; SOR: sorafenib; SEM:standard error of the mean.

    Techniques Used: Colony Assay, Control, Knock-Out

    Immunofluorescent evaluation of (A) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR, and (B) colocalization of PER2 and CK1ε in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR. PER2: Period 2; CK1ε: casein kinase 1ε; EveR: everolimus-resistant; SorR: sorafenib-resistant.
    Figure Legend Snippet: Immunofluorescent evaluation of (A) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR, and (B) colocalization of PER2 and CK1ε in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR. PER2: Period 2; CK1ε: casein kinase 1ε; EveR: everolimus-resistant; SorR: sorafenib-resistant.

    Techniques Used: Expressing

    (A) PER2 and p53 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. White arrows indicate the co-expression of PER2 and p53 proteins. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, **** P < 0.0001; (B) Protein-Protein Interaction Networks Functional Enrichment Analysis using STRING software to analyze and visualize the network connection among PER2, MDM2, p53, p21, and c-MYC; (C) Western blot analysis of PER2, MDM2, p53, p21, and c-MYC parental PLC/PRF/5, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; SEM: standard error of the mean; MDM2: mouse double minute 2 homolog; c-MYC: cellular myelocytomatosis oncogene.
    Figure Legend Snippet: (A) PER2 and p53 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. White arrows indicate the co-expression of PER2 and p53 proteins. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, **** P < 0.0001; (B) Protein-Protein Interaction Networks Functional Enrichment Analysis using STRING software to analyze and visualize the network connection among PER2, MDM2, p53, p21, and c-MYC; (C) Western blot analysis of PER2, MDM2, p53, p21, and c-MYC parental PLC/PRF/5, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; SEM: standard error of the mean; MDM2: mouse double minute 2 homolog; c-MYC: cellular myelocytomatosis oncogene.

    Techniques Used: Expressing, Functional Assay, Software, Western Blot, Knockdown, Knock-Out



    Similar Products

    human per2 hdr plasmid  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology human per2 hdr plasmid
    (A) In silico analysis of <t>PER2</t> mRNA expression in LIHC samples (purple boxplot) from TCGA cohort (obtained from RNAseq) compared with normal liver tissues (grey boxplot); (B) In silico analysis of PER2 mRNA expression in different stages of LIHC; (C) and (D) In silico analysis of PER2 mRNA expression in HCC cell lines from CCLE based on a dataset posted in 2022; (C) A comparison of PER2 mRNA expression between HCC and hepatoblastoma cell lines; and (D) a comparison of PER2 mRNA expression in HCC cell lines derived from human primary HCC, HCC cell lines with no clear origin, and HCC cell lines derived from human HCC metastasis; (E) Kaplan-Meier curve to assess the overall survival rate of patients with HCC depending on the PER2 gene expression; (F) SOR effect on cell line proliferation. Cell proliferation evaluated by DNA assay in PLC/PRF/5 cells: parental (black bars) and SorR (gray bars). The data presented are mean ± SEM of three independent experiments. * P < 0.05, *** P < 0.001 between groups; (G) PER2 mRNA expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, PLC/PRF/5 SorR, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO relative to HPRT housekeeping gene. * P < 0.05; ** P < 0.01; *** P < 0.001; (H) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO with related densitometry. **** P < 0.0001. PER2: Period 2; LIHC: Liver Hepatocellular Carcinoma; CCLE: Cancer Cell Line Encyclopaedia; TCGA: The Cancer Genome Atlas; HCC: hepatocellular carcinoma; SOR: sorafenib; SEM: standard error of the mean; EveR: everolimus-resistant; SorR: sorafenib-resistant; KD: knockdown; KO: knockout; HPRT: Hypoxanthine Phosphoribosyltransferase 1.
    Human Per2 Hdr Plasmid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+per2+hdr+plasmid/pmc12162184-64-17-30?v=Santa+Cruz+Biotechnology
    Average 93 stars, based on 1 article reviews
    human per2 hdr plasmid - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) In silico analysis of PER2 mRNA expression in LIHC samples (purple boxplot) from TCGA cohort (obtained from RNAseq) compared with normal liver tissues (grey boxplot); (B) In silico analysis of PER2 mRNA expression in different stages of LIHC; (C) and (D) In silico analysis of PER2 mRNA expression in HCC cell lines from CCLE based on a dataset posted in 2022; (C) A comparison of PER2 mRNA expression between HCC and hepatoblastoma cell lines; and (D) a comparison of PER2 mRNA expression in HCC cell lines derived from human primary HCC, HCC cell lines with no clear origin, and HCC cell lines derived from human HCC metastasis; (E) Kaplan-Meier curve to assess the overall survival rate of patients with HCC depending on the PER2 gene expression; (F) SOR effect on cell line proliferation. Cell proliferation evaluated by DNA assay in PLC/PRF/5 cells: parental (black bars) and SorR (gray bars). The data presented are mean ± SEM of three independent experiments. * P < 0.05, *** P < 0.001 between groups; (G) PER2 mRNA expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, PLC/PRF/5 SorR, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO relative to HPRT housekeeping gene. * P < 0.05; ** P < 0.01; *** P < 0.001; (H) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO with related densitometry. **** P < 0.0001. PER2: Period 2; LIHC: Liver Hepatocellular Carcinoma; CCLE: Cancer Cell Line Encyclopaedia; TCGA: The Cancer Genome Atlas; HCC: hepatocellular carcinoma; SOR: sorafenib; SEM: standard error of the mean; EveR: everolimus-resistant; SorR: sorafenib-resistant; KD: knockdown; KO: knockout; HPRT: Hypoxanthine Phosphoribosyltransferase 1.

    Journal: Cancer Drug Resistance

    Article Title: PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

    doi: 10.20517/cdr.2024.193

    Figure Lengend Snippet: (A) In silico analysis of PER2 mRNA expression in LIHC samples (purple boxplot) from TCGA cohort (obtained from RNAseq) compared with normal liver tissues (grey boxplot); (B) In silico analysis of PER2 mRNA expression in different stages of LIHC; (C) and (D) In silico analysis of PER2 mRNA expression in HCC cell lines from CCLE based on a dataset posted in 2022; (C) A comparison of PER2 mRNA expression between HCC and hepatoblastoma cell lines; and (D) a comparison of PER2 mRNA expression in HCC cell lines derived from human primary HCC, HCC cell lines with no clear origin, and HCC cell lines derived from human HCC metastasis; (E) Kaplan-Meier curve to assess the overall survival rate of patients with HCC depending on the PER2 gene expression; (F) SOR effect on cell line proliferation. Cell proliferation evaluated by DNA assay in PLC/PRF/5 cells: parental (black bars) and SorR (gray bars). The data presented are mean ± SEM of three independent experiments. * P < 0.05, *** P < 0.001 between groups; (G) PER2 mRNA expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, PLC/PRF/5 SorR, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO relative to HPRT housekeeping gene. * P < 0.05; ** P < 0.01; *** P < 0.001; (H) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, and PLC/PRF/5 PER2 KO with related densitometry. **** P < 0.0001. PER2: Period 2; LIHC: Liver Hepatocellular Carcinoma; CCLE: Cancer Cell Line Encyclopaedia; TCGA: The Cancer Genome Atlas; HCC: hepatocellular carcinoma; SOR: sorafenib; SEM: standard error of the mean; EveR: everolimus-resistant; SorR: sorafenib-resistant; KD: knockdown; KO: knockout; HPRT: Hypoxanthine Phosphoribosyltransferase 1.

    Article Snippet: The cells were co-transfected with 2 μg of human PER2 KO plasmid (sc-401089-KO-2) and 2 μg of human PER2 HDR plasmid (sc-401089-HDR-2) using 10 μL of UltraCruz Transfection Reagent (sc-395739, Santa Cruz Biotechnology, Inc.) in a final volume of 150 μL Plasmid Transfection Medium (sc-108062, Santa Cruz Biotechnology, Inc.).

    Techniques: In Silico, Expressing, Comparison, Derivative Assay, Gene Expression, Knockdown, Knock-Out

    Evaluation of E-cadherin, vimentin and ZEB1 protein expression by immunofluorescent imaging in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. ZEB1: Zinc finger E-box binding homeobox 1; PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant.

    Journal: Cancer Drug Resistance

    Article Title: PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

    doi: 10.20517/cdr.2024.193

    Figure Lengend Snippet: Evaluation of E-cadherin, vimentin and ZEB1 protein expression by immunofluorescent imaging in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. ZEB1: Zinc finger E-box binding homeobox 1; PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant.

    Article Snippet: The cells were co-transfected with 2 μg of human PER2 KO plasmid (sc-401089-KO-2) and 2 μg of human PER2 HDR plasmid (sc-401089-HDR-2) using 10 μL of UltraCruz Transfection Reagent (sc-395739, Santa Cruz Biotechnology, Inc.) in a final volume of 150 μL Plasmid Transfection Medium (sc-108062, Santa Cruz Biotechnology, Inc.).

    Techniques: Expressing, Imaging, Control, Binding Assay, Knockdown, Knock-Out

    Cell proliferation evaluated by DNA assay in PLC/PRF/5 PER2 KD (A) and PLC/PRF/5 PER2 KO (B) with and without treatment with EVE (10 -9 M) and (SOR 5 × 10 -6 M). Cell migration evaluation by analysis of wound coverage in PLC/PRF/5 PER2 KD (C) and PLC/PRF/5 PER2 KO (D) and by scratch assay (E) with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M) compared to parental PLC/PRF/5. The data presented in the graphs are mean ± SEM of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KD: knockdown; KO: knockout; EVE: everolimus; SOR: sorafenib; SEM: standard error of the mean.

    Journal: Cancer Drug Resistance

    Article Title: PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

    doi: 10.20517/cdr.2024.193

    Figure Lengend Snippet: Cell proliferation evaluated by DNA assay in PLC/PRF/5 PER2 KD (A) and PLC/PRF/5 PER2 KO (B) with and without treatment with EVE (10 -9 M) and (SOR 5 × 10 -6 M). Cell migration evaluation by analysis of wound coverage in PLC/PRF/5 PER2 KD (C) and PLC/PRF/5 PER2 KO (D) and by scratch assay (E) with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M) compared to parental PLC/PRF/5. The data presented in the graphs are mean ± SEM of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KD: knockdown; KO: knockout; EVE: everolimus; SOR: sorafenib; SEM: standard error of the mean.

    Article Snippet: The cells were co-transfected with 2 μg of human PER2 KO plasmid (sc-401089-KO-2) and 2 μg of human PER2 HDR plasmid (sc-401089-HDR-2) using 10 μL of UltraCruz Transfection Reagent (sc-395739, Santa Cruz Biotechnology, Inc.) in a final volume of 150 μL Plasmid Transfection Medium (sc-108062, Santa Cruz Biotechnology, Inc.).

    Techniques: Migration, Wound Healing Assay, Control, Knockdown, Knock-Out

    Images and statistical assessment of colony number (A, C, E, G and I) and size (B, D, F, H, and L) evaluated by colony formation assay in parental PLC/PRF/5, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and SorR with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M). The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; EVE: everolimus; SOR: sorafenib; SEM:standard error of the mean.

    Journal: Cancer Drug Resistance

    Article Title: PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

    doi: 10.20517/cdr.2024.193

    Figure Lengend Snippet: Images and statistical assessment of colony number (A, C, E, G and I) and size (B, D, F, H, and L) evaluated by colony formation assay in parental PLC/PRF/5, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and SorR with and without treatment with EVE (10 -9 M) and SOR (5 × 10 -6 M). The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 vs. control or among the groups. PER2: Period 2; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; EVE: everolimus; SOR: sorafenib; SEM:standard error of the mean.

    Article Snippet: The cells were co-transfected with 2 μg of human PER2 KO plasmid (sc-401089-KO-2) and 2 μg of human PER2 HDR plasmid (sc-401089-HDR-2) using 10 μL of UltraCruz Transfection Reagent (sc-395739, Santa Cruz Biotechnology, Inc.) in a final volume of 150 μL Plasmid Transfection Medium (sc-108062, Santa Cruz Biotechnology, Inc.).

    Techniques: Colony Assay, Control, Knock-Out

    Immunofluorescent evaluation of (A) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR, and (B) colocalization of PER2 and CK1ε in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR. PER2: Period 2; CK1ε: casein kinase 1ε; EveR: everolimus-resistant; SorR: sorafenib-resistant.

    Journal: Cancer Drug Resistance

    Article Title: PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

    doi: 10.20517/cdr.2024.193

    Figure Lengend Snippet: Immunofluorescent evaluation of (A) PER2 protein expression in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR, and (B) colocalization of PER2 and CK1ε in PLC/PRF/5 parental, PLC/PRF/5 EveR, and PLC/PRF/5 SorR. PER2: Period 2; CK1ε: casein kinase 1ε; EveR: everolimus-resistant; SorR: sorafenib-resistant.

    Article Snippet: The cells were co-transfected with 2 μg of human PER2 KO plasmid (sc-401089-KO-2) and 2 μg of human PER2 HDR plasmid (sc-401089-HDR-2) using 10 μL of UltraCruz Transfection Reagent (sc-395739, Santa Cruz Biotechnology, Inc.) in a final volume of 150 μL Plasmid Transfection Medium (sc-108062, Santa Cruz Biotechnology, Inc.).

    Techniques: Expressing

    (A) PER2 and p53 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. White arrows indicate the co-expression of PER2 and p53 proteins. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, **** P < 0.0001; (B) Protein-Protein Interaction Networks Functional Enrichment Analysis using STRING software to analyze and visualize the network connection among PER2, MDM2, p53, p21, and c-MYC; (C) Western blot analysis of PER2, MDM2, p53, p21, and c-MYC parental PLC/PRF/5, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; SEM: standard error of the mean; MDM2: mouse double minute 2 homolog; c-MYC: cellular myelocytomatosis oncogene.

    Journal: Cancer Drug Resistance

    Article Title: PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

    doi: 10.20517/cdr.2024.193

    Figure Lengend Snippet: (A) PER2 and p53 protein expression in PLC/PRF/5 parental, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. White arrows indicate the co-expression of PER2 and p53 proteins. The data presented in the graphs are mean ± SEM of two independent experiments. * P < 0.05, **** P < 0.0001; (B) Protein-Protein Interaction Networks Functional Enrichment Analysis using STRING software to analyze and visualize the network connection among PER2, MDM2, p53, p21, and c-MYC; (C) Western blot analysis of PER2, MDM2, p53, p21, and c-MYC parental PLC/PRF/5, PLC/PRF/5 PER2 KD, PLC/PRF/5 PER2 KO, PLC/PRF/5 EveR, and PLC/PRF/5 SorR cells. PER2: Period 2; KD: knockdown; KO: knockout; EveR: everolimus-resistant; SorR: sorafenib-resistant; SEM: standard error of the mean; MDM2: mouse double minute 2 homolog; c-MYC: cellular myelocytomatosis oncogene.

    Article Snippet: The cells were co-transfected with 2 μg of human PER2 KO plasmid (sc-401089-KO-2) and 2 μg of human PER2 HDR plasmid (sc-401089-HDR-2) using 10 μL of UltraCruz Transfection Reagent (sc-395739, Santa Cruz Biotechnology, Inc.) in a final volume of 150 μL Plasmid Transfection Medium (sc-108062, Santa Cruz Biotechnology, Inc.).

    Techniques: Expressing, Functional Assay, Software, Western Blot, Knockdown, Knock-Out